Tesofensine for Weight Loss: What the Trials Showed and Why It Isn't Approved

Tesofensine is an experimental weight-loss pill that is not approved by FDA, and as of October 2026 it is not approved in Mexico either, despite years of online claims that it is. It works in the brain, blocking the reuptake of three chemical messengers at once: dopamine, norepinephrine and serotonin. In its main published trial, people on the 0.5 mg dose lost 9.2% of their weight in 24 weeks against 2.0% on placebo,^[1] but that trial carries an expression of concern from The Lancet after regulators found that headache, stress and depression had not been reliably recorded.^[2][3] The drug raises heart rate, and the capsules sold online come with none of the monitoring the trials used.

What tesofensine is

Tesofensine is a small-molecule drug taken as a daily tablet. It is not a peptide, though it is often sold beside peptides. It blocks the transporters that clear dopamine, norepinephrine and serotonin from the gaps between nerve cells, so all three linger longer. Drugs with this profile are called triple reuptake inhibitors.^[1] A brain-imaging study found that daily doses of 0.125 to 1 mg occupied between 18% and 77% of the brain’s dopamine transporters, with about half the maximum effect reached at 0.25 mg.^[8]

It was not designed for obesity. The Danish company NeuroSearch and its partner Boehringer Ingelheim first tested it in Parkinson’s and Alzheimer’s disease, where it failed. What the trials did notice was weight loss. Pooling four of those trials, with 740 people on tesofensine and 228 on placebo, researchers found weight fell by up to 2.8% in 14 weeks on the 1 mg dose with no diet program at all, while placebo patients gained 0.5%.^[5][11] That finding sent the drug into obesity trials.

How it causes weight loss in people is mostly about appetite. In a two-week study in 32 overweight men told to eat as usual, tesofensine produced 1.8 kg more weight loss than placebo, raised feelings of fullness and lowered how much they expected to eat. Total daily energy use did not change significantly, though it rose 4.6% overnight and fat burning increased.^[6]

The 2008 Lancet trial

The study that made tesofensine famous was a phase 2 trial run at five Danish obesity centers and published in The Lancet in 2008. It randomized 203 adults with a BMI of 30 to 40 to tesofensine 0.25, 0.5 or 1.0 mg, or placebo, once a day for 24 weeks. Everyone was also put on a calorie-restricted diet. 161 people, 79%, finished.^[1]

Every dose beat placebo. The authors wrote that 0.5 mg might produce twice the weight loss of the obesity drugs available at the time, and that the findings needed confirmation in phase 3 trials.^[1] The appetite effect did not hold steady, though. In the same program, a fullness score rose by week 12 and then faded as weight came off, returning to baseline once the drug stopped. Restarting the drug raised it again.^[7]

The most common side effects were dry mouth, nausea, constipation, hard stools, diarrhea and insomnia. On 0.5 mg, resting heart rate rose by 7.4 beats per minute.^[1] Blood pressure did not rise significantly on the two lower doses; it did on the highest.^[1][11]

The Lancet’s expression of concern

In April 2013, The Lancet attached an expression of concern to the trial.^[2] The Danish Health and Medicines Authority had picked the study for a random inspection in November 2011 and raised problems at two of the five sites. At one, informed consent had been handed to staff who were not doctors, against Danish rules. The integrity of the blinding had been questioned in an earlier 2007 inspection, which the investigators rebutted. And the contract research organization had not recorded side effects completely.^[3]

“In particular, headache, migraine, stress, and depression were not reliably recorded in people who had experienced these conditions before enrolling in the trial.”^[3]

— The Lancet, expression of concern, April 2013, as reproduced by Retraction Watch

The inspection report concluded that the side-effect profile published in the journal did not match what had actually happened in the trial.^[3] The lead author said the problems arose at other centers and with the sponsor and its contractor, not his own department, and the authors answered in a published letter.^[4][3] The weight-loss figures were not withdrawn. But the paper most often quoted for tesofensine’s safety is the one whose safety reporting a regulator found incomplete, and the gap fell on mood and headache, the very side effects a drug acting on dopamine and serotonin would be expected to cause.

Heart rate and blood pressure

Tesofensine speeds the heart, and the rise grows with the dose. In the pooled Parkinson’s and Alzheimer’s trials, heart rate rose by 2.1 beats per minute on 0.125 mg up to 6.8 on 1 mg after 14 weeks, against a fall of 0.4 on placebo, without a change in blood pressure.^[5] In the obesity trial, it was 7.4 beats per minute on 0.5 mg.^[1] An independent evaluation of that trial concluded that tesofensine raised both blood pressure and heart rate, and said its tolerability needed testing in large phase 3 trials.^[10]

The developers treated the heart-rate effect as a real problem. In rats, the company showed that adding metoprolol, a beta blocker, “fully prevented” the rises in heart rate and blood pressure without blunting the appetite effect.^[13] That became Tesomet, a fixed pill of tesofensine 0.5 mg and metoprolol 50 mg. In a 24-week trial in 21 adults with hypothalamic obesity, Tesomet added 6.3% weight loss over placebo with no difference in heart rate or blood pressure.^[14] Capsules bought online contain tesofensine alone.

Sibutramine, the drug tesofensine was most often compared with, also worked on norepinephrine and serotonin.^[5] It was withdrawn from the market in 2010 after a large outcomes trial linked it to more heart attacks and strokes.^[29] No cardiovascular outcomes trial of tesofensine has been run.^[28]

Mood, sleep and abuse potential

Insomnia is the side effect most consistently linked to tesofensine, as it is to other drugs that act on the same chemical messengers, including sibutramine and bupropion.^[12][1] Mood is less clear because of the reporting problems above. The independent evaluation of the 2008 trial listed depressed mood among the side effects on 0.5 mg and said the drug may increase psychiatric disorders.^[10] In the small Tesomet trial, sleep disturbances hit 50% on the drug against 13% on placebo, and one patient stopped because of worsened anxiety that had been present before the trial.^[14]

Because tesofensine blocks dopamine reuptake, regulators wanted to know whether it could be abused like a stimulant. In a single-dose study of 52 recreational stimulant users, its effects on the main drug-liking measures did not differ significantly from placebo and were lower than amphetamine’s; the authors judged its abuse potential no greater than that of bupropion or atomoxetine.^[9] That was one dose in a clinic. It says little about daily use for months. Sports bodies treat it as a stimulant: the World Anti-Doping Agency lists tesofensine under prohibited stimulants in competition.^[19]

Anyone with a history of depression, anxiety, bipolar disorder, an eating disorder, heart rhythm problems or high blood pressure would have been watched closely in a trial. Someone taking a vendor’s capsule has nobody watching.

Is tesofensine approved? FDA and Mexico

United States. No. FDA’s drug-approval database and the DailyMed label library return no tesofensine product. It does not appear on FDA’s lists of substances nominated for use by compounding pharmacies,^[27] so there is no lawful compounded version either. The US Tesomet program has FDA orphan drug designations for rare obesity disorders, but its two US trials were withdrawn before enrolling anyone.^[17][28]

Mexico. Also no, as of October 2026. Saniona, the Danish company that now holds tesofensine, has licensed Mexico and Argentina to the Mexican drugmaker Medix. Medix ran a phase 3 trial and applied to COFEPRIS, Mexico’s drug regulator. A COFEPRIS technical committee gave a favorable, non-binding opinion in February 2023.^[17][18] In November 2024, Saniona announced that Medix had not received approval.^[15] In February 2025, it said Medix was revising the application on COFEPRIS’s feedback and would resubmit.^[16] Saniona’s August 2026 report still says Medix “continues to pursue regulatory approval.”^[17] Online claims that tesofensine is “approved in Mexico” are not supported by the company that owns it.

What the phase 3 trial reported

Medix’s phase 3 trial enrolled 372 people with obesity, tested 0.25 and 0.5 mg against placebo for 24 weeks alongside diet and exercise, and according to Saniona produced about 10% average weight loss on 0.5 mg, with more than half of patients losing over 10%.^[15][17] Saniona describes the safety as similar to placebo, with no significant blood-pressure effect and “a minor but statistically significant increase in heart rate.”^[17]

Those are company statements. The trial has not appeared in a peer-reviewed journal, it is not registered on ClinicalTrials.gov,^[28] and the placebo group’s result has not been disclosed, so the drug’s effect over placebo cannot be calculated. It also ran for 24 weeks, the same short span as the phase 2 trial.

Tesofensine against approved weight-loss drugs

Tesofensine was once pitched as a drug that could double the weight loss of 2008-era medicines.^[1] The bar has moved since. The table below sets its trial results beside the pivotal trials of drugs FDA has approved for chronic weight management.

On paper, tesofensine’s six-month figure sits in the range of the approved pills and below the weekly GLP-1 shots, which were measured over more than a year. What no placebo-controlled tesofensine trial has reported is what happens after six months on the drug: whether weight keeps falling, holds or returns, and what a year or more of a faster heart does. The appetite data already showed the effect fading by week 24.^[7] The approved drugs went through year-long trials with thousands of people before reaching a pharmacy.

How tesofensine is sold online, and the GLP-1 overlap

Tesofensine is sold online as capsules marketed as a dietary supplement,^[19] as 0.5 mg tablets, and as powder in chemical catalogs labeled for “research use only.” None of these is an approved product. An anti-doping lab in Germany bought one of the supplements from an internet supplier for a 2026 study. Each capsule was labeled 500 mcg of tesofensine, the trial dose, and tested at 483 mcg.^[19] That one product was close to its label. It proves nothing about the next one, and the dose being right does not make it safe.

The research label carries no legal weight for drugs sold to people. In a December 2024 warning letter to a seller of GLP-1 vials, FDA said that despite labels reading “RESEARCH USE ONLY” and “INTENDED AS A RESEARCH CHEMICAL ONLY,” the seller’s websites showed the products were “intended to be drugs for human use.”^[26] Why that wording protects the seller rather than the buyer is laid out in buying tirzepatide as a research chemical, and the same pattern for a pipeline drug is covered in retatrutide’s phase 3 and the gray market.

Some people already on a GLP-1 add tesofensine to push past a plateau or tame appetite. No trial has tested that combination; the registered tesofensine studies cover obesity alone, Parkinson’s, Alzheimer’s and Tesomet.^[28] One overlap is predictable, though. GLP-1 drugs raise resting heart rate too: Wegovy’s label reports an average rise of 1 to 4 beats per minute over placebo, with 26% of people having a rise of 20 or more at some visit against 16% on placebo, and Zepbound’s label reports 1 to 3 beats.^[24][25] Stacking two drugs that each speed the heart, one of them untested for longer than six months, is an experiment with no data behind it. The closest studied pairing, an older stimulant with a GLP-1, is covered in phentermine and a GLP-1 together.

Two more details matter for anyone doing this. Tesofensine leaves the body slowly, with a plasma half-life of more than 200 hours, so it builds up over weeks and side effects do not stop the day the capsules do.^[19] And because it is a pill, it is often treated as milder than an injection. It is not: it acts directly on brain chemistry, which a GLP-1 shot does only indirectly. For the regulatory status of the peptides sold on the same pages, see are peptides legal; for which of them have human trials at all, see the peptide menu review. The drugs that are moving toward approval are tracked on our GLP-1 pipeline page.